Radiologic Imaging: A Window into Disease Diagnosis and Management

Pooja Nair*

Department of Neuroradiology, Dibrugarh University, India

Abstract

Üæåâ[|[*â&ǻ{æ*â}*Å•cæ}å•ǽ•ǽ&¦˘&åæ|Å]â||æ¦ǻ}Å&[}c^{][¦æ¦ˆÅ@^æ|c@&æ¦^ÊÅ[^¦â}*Å&|â}â&åæ}•ǽÅ]¦[˘}åÅˇ}å^¦•cæ}åâ}*Å[-Åâå•^æ•^Å]æc@[|[*ˆÅæ}åÅ*˘âåâ}*Å^^&càç^Å{æ}æ*^{^}cÅ•c¦æc^*â^•ÊÅV@â•Åæà•c¦æ&cÅ]¦[çâå^•Åæ}Å[ç^¦çâ^¸Å[-Åc@^Å]âç[cæ|Å role of radiologic imaging in disease diagnosis and management. It explores the diverse imaging modalities, including X-ray, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and nuclear medicine imaging, each

Ke, o_d :

In _od c ion

*Corresponding author: Pooja Nair, Department of Neuroradiology, Dibrugarh University, India, E-mail: Nairpooja698@gmail.in

Clinical application

Advancement and future direction

Conclusion

References

1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.

2. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255.

3. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68: 723-750.

4. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, et al. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382: 1894-1905.

5. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, et al. (2015) Adjuvant Sorafenib for Hepatocellular Carcinoma after Resection or Ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16: 1344-1354.

6. Khor B, Gardet A, Xavier RJ (2011) Õ^}^ɑ&•/æ}ɑÅ]æc@[*^}^•ɑ•Å[-Åä}'æ{{æc[¦^Å bowel disease. Nature 474: 307-317.